Study type: Human research · Status: Verified against declared source

SS-31, a Mitochondria-Targeting Chemical sequence, Ameliorates Kidney Disease.

Oxidative medicine and cellular longevity · 2022

Study scale: Using an IR kidney injury model, Szeto et al.

Product or molecular entity relationships

SS-31: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

SS peptides are novel mitochondria-targeting antioxidants centered on alternating aromatic residues and basic amino acids, which were discovered fortuitously by Szeto and Schiller while carrying out studies on opioid receptors [12].

Methods

Mitochondrial dysfunction is involved in the development and progression of kidney disease, and methods to target mitochondria for disease treatment have been developed.

Scale or participants

Using an IR kidney injury model, Szeto et al.

Key findings

Mitochondria are essential for eukaryotic cell activity and function, and their dysfunction is associated with the development and progression of renal diseases.

Limitations and uncertainty

Mitochondria are essential for eukaryotic cell activity and function, and their dysfunction is associated with the development and progression of renal diseases.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.